stockrowAprea Therapeutics, Inc.
APRE Healthcare Biotechnology
Aprea Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $285,800.00, down 81.0% from fiscal 2024.
- Revenue
- −98.4%
- EPS
- +80.9%
- Free cash flow
- −5.22%
Quarter to September 2026, against a year earlier
Follow APRE
Alert me
Aprea Therapeutics, Inc. (APRE) EV/Sales
As of 6 November 2026, Aprea Therapeutics, Inc. (APRE) trades at a EV/Sales of −34.8×. Over the past ten years it has ranged from −127× (June 2026) to 39.1× (August 2026); the current reading is higher than 5% of that period. That is below the Biotechnology industry median of 9.0× and below the Healthcare sector median of 3.6×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −31.6× | — |
| FY2024 | −3.1× | — |
| FY2023 | 0.0× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Dec 2025 | −31.6× | — |
| Sep 2025 | −8.8× | — |
| Jun 2025 | −7.4× | — |
| Mar 2025 | −5.5× | — |
| 7 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| AIM AIM ImmunoTech Inc. compare | −71.4× |
| APRE Aprea Therapeutics, Inc. | −34.8× |
| EVGN Evogene Ltd. compare | −3.6× |
| KPRX Kiora Pharmaceuticals, Inc. compare | −0.4× |
| ENVB Enveric Biosciences, Inc. compare | −0.1× |
| CNSP CNS Pharmaceuticals, Inc. compare | n/m |
| FBLG FibroBiologics Inc. compare | n/m |
| SYBX Synlogic, Inc. compare | 0.1× |
| XCUR Exicure, Inc. compare | 0.2× |
| Biotechnology industry median | 9.0× |
| Healthcare sector median | 3.6× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)